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Introduction
GM1-gangliosidosis (OMIM 230500; OMIA ID: 000402) is a rare
autosomal recessive disease characterized by lysosomal storage
of GM1-ganglioside due to deficiency of -galactosidase activity
(GLB1; EC 3.2.1.23) [1]. In humans, the consequence of GM1-
ganglioside accumulation in the central nervous system is a pro-
gressive cerebellar dysfunction [2–4]. The clinical phenotypes
depend on the type of mutations and can be correlated with
defects in GLB1 maturation [5, 6]. Over 20% of the humans suf-
fering from GM1-gangliosidosis display mutations in the exon 15
of the GLB1 gene. Exon 2 is only affected in 6% of the cases [7,
8]. The three forms of GM1-gangliosidosis in humans: infantile
(type I), late infantile/juvenile (type II) and adult (type III) are
characterized by a different age of onset and temporal evolution
[9–12]. The precise molecular mechanisms behind these three
forms are not clearly understood. Thus, to develop specific
therapies for humanGM1-gangliosidosis it is vital to use appropri-
ate animal models for each form of the disease. Canine GM1-gan-
gliosidosis resembles the human disease with respect to genetic
defects, biochemical abnormalities, clinical and pathological 
findings [3, 13–15]. GM1-gangliosidosis occurs naturally in five 
dog breeds: mixed-breed beagles, English springer spaniels,
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Abstract
GM1-gangliosidosis is a lysosomal storage disorder caused by a deficiency of ß-galactosidase activity. Human GM1-gangliosidosis has
been classified into three forms according to the age of clinical onset and specific biochemical parameters. In the present study, a canine
model for type II late infantile human GM1-gangliosidosis was investigated ‘in vitro’ in detail.  For a better understanding of the molecular
pathogenesis underlying GM1-gangliosidosis the study focused on the analysis of the molecular events and subsequent intracellular pro-
tein trafficking of -galactosidase. In the canine model the genetic defect results in exclusion or inclusion of exon 15 in the mRNA tran-
scripts and to translation of two mutant precursor proteins. Intracellular localization, processing and enzymatic activity of these mutant
proteins were investigated. The obtained results suggested that the -galactosidase C-terminus encoded by exons 15 and 16 is neces-
sary for correct C-terminal proteolytic processing and enzyme activity but does not affect the correct routing to the lysosomes. Both
mutant protein precursors are enzymatically inactive, but are transported to the lysosomes clearly indicating that the amino acid
sequences encoded by exons 15 and 16 are necessary for correct folding and association with protective protein/cathepsin A, whereas
the routing to the lysosomes is not influenced. Thus, the investigated canine model is an appropriate animal model for the human late
infantile form and represents a versatile system to test gene therapeutic approaches for human and canine GM1-gangliosidosis. 
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Portuguese water dogs, Shiba Inn dogs and Alaskan huskies. The
molecular defects responsible for GM1-gangliosidosis in dogs
were described only for the last three breeds [4, 16, 17, 18].
Thus, in Portuguese water dogs with GM1-gangliosidosis exon 2
of GLB1 gene is mutated, while for Shiba dogs the mutation
occurs in exon 15 [16, 18]. In Shiba dogs the disease is milder
than the late infantile GM1-gangliosidosis in humans with slightly
later onset and longer survival period [3, 8, 16]. In the present
study, we describe at the molecular level a canine Alaskan husky
model for the late infantile type II GM1-gangliosidosis.
The genetic defect in Alaskan huskies with GM1-gangliosidosis
is represented by a 19 bp duplication, in exon 15 of the canine
GLB1 gene, which partially disrupts a potential exon splicing
enhancer (ESE) leading to exon 15 skipping in a fraction of the
transcripts. The other transcripts retained the mutated exon 15,
which generates a premature termination codon [4, 17]. As a
result of these genetic modification a severe deficiency in the
GLB1 enzymatic activity (only 1–10% compared to homozygous
healthy dogs) can be found and results in a massive accumulation
of GM1-gangliosides in various cells especially in neurons of the
central nervous system in affected homozygous individuals [14,
17]. Clinically, the first disease signs are present at 6–8 weeks
after birth and progressed steadily until death of the affected indi-
viduals at the 9–12 months of age. The diseased animals show
signs of progressive cerebellar dysfunctions including ataxia and
spasticity similar to those observed in humans with late infantile
GM1-gangliosidosis [13, 14, 17]. 
Like all lysosomal enzymes, human GLB1 is transported to its
final destination along the secretory pathways [19, 20]. Thus, the
84 kDa human GLB1 precursor synthesized on ribosomes
contains an N-terminal signal sequence (ss) which targets its
co-translational translocation in the endoplasmic reticulum (ER)
[21, 22]. After the proteolytic cleavage of this signal sequence,
the nascent protein undergoes glycosylation in the ER and further
in Golgi compartments [23, 24]. Subsequently, the precursor
protein is phosphorylated and mannose-6-phosphate targeted to
the lysosomes [20,  25]. Here, in an acidic environment, the
human GLB1 precursor protein is processed to a mature enzyme
by proteolytic modification at the C-terminal region. The resulting
proteolytic fragments (64 and 22 kDa) generate the fully active
GLB1 [26]. Finally, the 64 kDa fragment of GLB1 is degraded to
an 18 and respectively 50 kDa fragments by cathepsin-B like thiol
proteases [24]
Along these secretory pathways, the human GLB1 forms com-
plexes with protective protein/ cathepsin A (PPCA) and N-acetyl-
-neuraminidase (NEU.1; EC 3.2.1.18) which are essential for
intracellular routing and maintenance of GLB1 activity [26, 27].
Without PPCA, human GLB1 is abnormally cleaved to inactive 80
and 72 kDa peptides [24].  
For a better understanding of the molecular mechanisms
underlying GM1-gangliosidosis in both the canine disease and
human late infantile type II form, the present study focused on the
analysis of the molecular events which connect the genetic defects
to the lack of GLB1 activity. Therefore, the possible association
between the absence of GLB1 activity and the abnormal process-
ing of the canine GLB1 mutants or impaired transport to the lyso-
somes was investigated. This was accomplished by following the
GLB1 proteins from the synthesis on the ribosomes until their final
destination, the lysosomes. 
Materials and methods
Computer-aided analyses
The canine N-terminal signal sequence necessary for GLB1 translocation
into the ER was predicted using the SignalP 3.0 software [28, 29]. To iden-
tify the putative N-linked glycosylation sites the amino acid sequence of
GLB1 was screened with the NetNGlyc software [30]. The Protein
Calculator v3.3. was used to estimate the molecular weight of the proteins. 
RNA isolation and cDNA synthesis
Total RNA was isolated from skin fibroblasts of healthy and affected dogs
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). A DNase (Qiagen,
Hilden, Germany) treatment was performed according to the manufactur-
er’s instructions. The synthesis of full length wild-type and mutant canine
GLB1 cDNAs was performed using the SMARTTM RACE method (Clontech,
Palo Alto, CA, USA).
Expression vector construction
The obtained cDNAs were amplified by PCR using the proof-reading KOD
HotStart® polymerase (Novagen, Darmstadt, Germany). The N-terminal
signal sequence was amplified using 5-atatggctagctccaccatggcggggttc-
ctggttcgcatcctc-3upstream and 5-ggtggcgaccggtccctgggtggcattgcgcaa-
3downstream primers which include the recognition sites for NheI and
AgeI, respectively. For amplification of the wild-type (GLB1) and the mutant
sequence lacking exon 15 (GLB1-delEx15), the 5-atatcgagctcaactgcggaat-
gcttcccagagg-3 upstream and 5-atccgcccgggcttcagtggtggtggtggtggtgga-
catagtccagtctcaa-3 downstream primers were used. For the mutant
sequence harboring the 19 bp duplication in exon 15 (GLB1-19bpdupl), the
following downstream primer 5-ccgcccgggcttcagtggtggtggtggtggtgatcca-
cacctgacccttg-3 was applied. Both downstream primers contained a
nucleotide tag encoding six histidine residues (6xHis). 
The constructs designed to encode GLB1 proteins contained the
enhanced cyan fluorescent protein (ECFP) sequence flanked at the 5end
by the canine N-terminal signal sequence and at the 3end by the wild type
or the mutant GLB1 sequences without their internal N-terminal signal
sequence (-iss). The ss was cloned in the NheI/AgeI site of the pECFP-C1®
Vector (Takara Bio Europe, Saint-Germain-en-Laye, France) while the wild-
type and the mutant GLB1 sequences harboring the 6xHis tag at their C-
terminus were introduced between the SacI and XmaI sites. Thus, three
vectors ss-ECFP-(-iss)-GLB1-His, ss-ECFP-(-iss)-GLB1delEx15-His and
ss-ECFP-(-iss)-GLB1-19bpdupl-His were produced (Fig. 1). The identity of
all obtained constructs was confirmed by sequencing (Agowa GmbH,
Berlin, Germany).
Cell culture procedures and transfection
The primary canine GLB1+/+ and GLB1-/- fibroblasts obtained from healthy
and respectively from affected Alaskan huskies and Madin-Darby Canine
Kidney (MDCK) cells (ATCC CCL-34) were maintained in Modified Eagle’s
Medium (MEM) with 10% foetal calf serum (FCS), 1 mM sodium pyruvate
and 1% penicillin/streptomycin at 37°C in a water-saturated 5% CO2 envi-
ronment [14]. All reagents were purchased from PAA Laboratories GmbH,
Pasching, Austria. Subsequently, the cells were plated in 6-well plates
(Nunc GmbH & Co. KG, Wiesbaden, Germany) before transfection. For
lysosomal staining procedures and confocal microscopy analyses, cells
were grown on cover slips. Subsequently, the cells were transfected with
Lipofectamine 2000® (Invitrogen, Karlsruhe, Germany) according to the
manufacturer’s instructions after they reached 60–70% confluence.
Protein extractions
Twenty-four hours after transfection, cells were collected by scraping on
ice, centrifuged at 4°C and then resuspended in 50 µl distilled water. To
obtain the total protein extracts three cycles of freezing in liquid nitrogen
and thawing at 37°C in a water bath were performed. All steps were 
done in the presence of 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml 
pepstatin, 5 µg/ml leupeptin, and 5 µg/ml aprotinin (Sigma-Aldrich,
Taufkirchen, Germany).
GLB1 enzymatic assays
GLB1 activity was measured using 4-methylumbelliferyl--D-galactopyra-
noside (4-MU-G, Sigma-Aldrich, Taufkirchen, Germany) as previously
described [14, 31–33]. Briefly, GLB1 cleaves 4-MU-G to galactose and the
fluorescent compound (4-MU). The 4-MU released is measured at 365 nm
and 455 nm and the GLB1 activity is given in mU/mg protein. Fibroblasts
from Alaskan huskies GLB1+/+ dogs were used as positive controls. 
Normalization of GLB1 activities
The GLB1 activities were normalized by using the amount of total protein
and transfection efficiency. The transfection efficiencies were expressed as
the percentage of ECFP-expressing cells [(ECFP-expressing cells / total
number of cells)  100]. Then, the GLB1 activity of the transfected cells
was extrapolated to 100% of transfection efficiency. For detection of GLB1
activity in transfected and non-transfected cells, the same number of cells
was used. Finally, the GLB1 activity was presented as mU/mg total protein.
All experiments were performed in triplicates.
SDS/PAGE and immunoblotting
Aliquots (10 µl) of total protein extracts were subjected to SDS-PAGE
analysis using a 10% (w/v) gel, followed by transfer to a nitrocellulose
membrane (Amersham HybondTM ECLTM, GE Healthcare, Freiburg,
Germany). Non-specific binding sites were blocked with 5% (w/v) skim
milk (Merck KGaA, Darmstadt, Germany) in PBS (phosphate buffered
saline) [34]. Then, the membrane was incubated either with BD Living
ColorTM A.v. Monoclonal Antibody (anti-ECFP antibody) (Clontech- Takara
Bio Europe, Saint-Germain-en-Laye, France) or with Penta-His antibodies
(anti-His antibody) (Qiagen, Hilden, Germany). After washing three times
with PBS, the membrane was incubated for 2 hrs with the secondary anti-
body, horseradish peroxidase-conjugated goat antimouse IgG (Sigma,-
Aldrich, Taufkirchen, Germany). For protein visualization the ECL System
(GE Healthcare, Freiburg, Germany) was used. 
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Fig. 1 Cloning strategy for generating fusion proteins used in the enzymatic assays and intracellular localization analyses; ss: signal sequence for translo-
cation in endoplasmic reticulum; ECFP, nucleotide sequence encoding the enhanced cyan fluorescent protein; XIV, XV, XVI, nucleotide sequences 
corresponding to exon 14, 15, 16 from the canine GLB1 gene; His, tag encoding for six histidine residues (6xHis tag).
Lysosomes staining and imaging
Acidic organelles were labelled with the acidotropic dye LysoTracker® Red
DND-99 (Invitrogen, Karlsruhe, Germany) or with anti lysosomal-associated
membrane protein 1 (LAMP-1) antibody (Acris Antibodies GmbH,
Hiddenhausen, Germany). For LysoTracker staining, cells were pre-incubated
for 30 min. with 50 nM LysoTracker dye 24 hrs after transfection. For
immunostaining with LAMP-1, the cells were washed with PBS and then
fixed with 4% paraformaldehyde for 30 min. at room temperature (RT). 
After an additional washing step, the cells were permeabilized with 0.25%
Triton-X (Sigma-Aldrich, Taufkirchen, Germany) in PBS (PBST) for 15 min..
To block unspecific binding sites, the cells were kept in 5% goat serum
(Sigma-Aldrich, Taufkirchen, Germany) in PBST for 30 min.. The cells were
then incubated overnight at 4°C with the LAMP-1 antibody diluted 1:1000 in
PBST. After 10 min. washing in PBST, cells were incubated for 30 min. with
Cy3 conjugated AffiniPure goat antimouse (Dianova GmbH, Hamburg,
Germany) diluted 1:200 in PBST. Then, the cells were washed with and kept
in PBS until embedded with Fluorescent mounting medium® (Dako
Deutschland GmbH, Hamburg, Germany). The cells labeled with LysoTracker
or with LAMP-1 followed by Cy3 were imaged with an inverted microscope
Leica DM IRE2 (Leica, Wetzlar, Germany) using a HeNe 543 nm laser. For
visualization of ECFP-fused proteins an Ar-Ion 488 nm laser was used. Full-
frame images (1024 pixels  1024 pixels) were taken with an oil immersion
objective (Plan-Apochromat 63/1.40 Oil DIC, Leica, Wetzlar, Germany),
with an interval of 0.5m and a flattened z-stack image of the confocal images
was generated.
Results
Predicted characteristics of canine
compared to human GLB1
Screening of the amino acid sequence with the SignalP 3.0 soft-
ware revealed a potential signal sequence at the N-terminus of
the canine GLB1 precursor protein. The identified potential
signal sequence was similar to the signal sequence for translo-
cation in the ER present in the human GLB1. To determine
whether the 29 amino acid long hydrophobic sequence has the
ability to drive the protein to the ER, the corresponding
nucleotide sequence was cloned in front of the ECFP sequence
for generating the ss-ECFP vector. Then, MDCK cells were
transfected with ECFP and ss-ECFP plasmids and the location of
these proteins was visualized by confocal microscopy. As
shown in Figure 2, those proteins containing the 29 amino acid
sequence at the N-terminus were driven into the ER and further
into the Golgi apparatus, whereas the proteins without this
sequence remained in the cytosol. For the human GLB1, the
cleavage site used for lysosomal maturation of the enzyme
was located in the amino acid sequence encoded by exon 15
(S543 F555). A similar cleavage locus (S544 F556) was identified in
the amino acid sequence encoded by exon 15 of the canine
GLB1 gene. This cleavage site is missing in the canine GLB1-
delEx15 mutant protein. Furthermore, by screening the canine
GLB1 amino acid sequence with the NetNGlyc software, six
putative N-glycosylation sites at positions N27, N248, N465, N499,
N546 and N556 in the wild-type canine GLB1 and the canine GLB1-
19bpdupl mutant protein and only three sites (N27, N248, N465) in
the canine GLB1-delEx15 mutant protein were identified.
Similarly, the human GLB1 contains a cleavage site at A594R595
which was involved in abnormal degradation in the absence of
PPCA [24]. In the canine GLB1 amino acid sequence this presump-
tive cleavage site is also present at positions A595R596. The predict-
ed size of glycosylated canine GLB1 precursor was 84 kDa. After
proteolytic cleavage in lysosomes, the putative sizes of the resulting
two fragments resulted were 64 and 20 kDa. Without the internal
signal sequence (-iss), the corresponding sizes for the mutant pre-
cursor proteins (GLB1-delEx15 and GLB1-19bpdupl) were 74.5 and
75.2 kDa respectively.
Intracellular localization, processing 
and enzymatic activity of wild type 
and mutant canine GLB1 
For the analysis of intracellular routing of the canine GLB1,
ECFP-fused canine GLB1-His-tagged proteins were used. To
demonstrate that the ECFP and His sequences do not modify the
normal behavior of GLB1 in the cells, the GLB1 activities from
MDCK, GLB1-/- and GLB1+/+ fibroblasts transfected with
ss-ECFP-(-iss)-GLB1-His and ss-(-iss)-GLB1 constructs were
compared. The GLB1 activity was similar in all transfected cells
(Fig. 3), therefore the ss-ECFP (-iss)-GLB1-His plasmids were
used for further experiments. To investigate if the canine GLB1
protein encoded by ss-ECFP-(-iss)-GLB1-His reached the
lysosomes, the MDCK cells were transfected with the ss-ECFP-
(-iss)-GLB1-His construct. The intracellular location of the GLB1
was assessed by confocal microscopy, after a specific staining
of the lysosomes with LysoTracker. Thus, as shown in Figure 4,
ECFP and LysoTracker fluorescence co-localized, indicating that
GLB1 protein reached the lysosomes. Similar results were
obtained after staining the lysosomes with LAMP-1 antibody
(data not shown).
To determine if the canine GLB1 undergoes similar lysosomal
proteolytic modifications as the human GLB1, Western blot analy-
ses were performed with antibodies against the ECFP and 6 x His
tag. As shown in Figure 5A line 1, the 110 kD (84 kD GLB1 + 
26 kD ECFP protein) ECFP-GLB1-His precursor protein is partially
processed to a 90 kD fragment (64 kD GLB1 + 26 kD ECFP pro-
tein) which represents the ECFP fused N-terminus proteolytic
fragment of the mature form of the enzyme produced in the lyso-
somes after cleavage at the S544F556 locus. Moreover, as a result
of further normal N-terminus degradation of GLB1 by resident
proteases a fragment of 44 kD (18 kD GLB1 + 26 kD ECFP protein)
was observed. Furthermore, beside the ECFP-GLB1-His precursor
protein of 110 kD (84 kD GLB1 + 26 kD ECFP protein), Western
blot analyses using an anti-His antibody revealed the presence of
a 20 kD specific polypeptide (Fig. 5B; line 1). This represents the
1664 © 2008 The Authors
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C-terminus proteolytic fragment of the mature GLB1 produced
after cleavage at the S544F556 locus. To examine whether this 
fragment is generated by lysosomal processing, a canine GLB1
protein designed to be retained in the ER was also analysed 
(ss-ECFP-(+iss)-GLB1). This protein showed neither processing to
the 90 and 44 kD fragments (Fig. 5A; line 2), nor to the 20 kD frag-
ment (Fig. 5B; line 2). This result confirmed the lysosomal origin
of the 20 kD fragment. To further determine whether possible 
processing differences between the wild type and the mutant 
proteins are responsible for the lack of the GLB1 activity in the
J. Cell. Mol. Med. Vol 12, No 5A, 2008
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Fig. 2 Localization of ECFP and ss-ECFP
proteins in MDCK cells, 24 hrs after trans-
fection; A: uniform cytoplasmic distribution
of ECFP protein; B: endoplasmic reticulum
and Golgi apparatus (arrows) distribution
of ss-ECFP protein.
Fig. 3 Influence of ECFP and His tag on canine GLB1 activity in MDCK cells, GLB1-/- and GLB1+/+ fibroblasts; the data shown that GLB1 activity (mU/mg)
increased after transfection with the wild-type GLB1 containing vectors, while no difference in GLB1 activity was detected between those cells transfected
with ss-(-iss)-GLB1-His or ss-ECFP-(-iss)-GLB1-His vectors; non-transfected - endogenous GLB1 activity in MDCK cells, GLB1-/- and GLB1+/+ fibroblasts;
ss-ECFP - GLB1 activity in cells transfected with the ss-ECFP construct; ss-(-iss)-GLB1 - GLB1 activity in cells transfected with the wild-type GLB1 without
ECFP and His tag; ss-ECFP-(-iss)-GLB1-His - GLB1 activity in cells transfected with the construct containing a signal sequence (ss) for internalization into
the ER, before ECFP sequence and the wild-type GLB1 without its signal sequence (-iss), fused to 6xHis at C-terminus.
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homozygous individuals carrying the 19 bp duplication, the intra-
cellular routing and the processing of the mutant proteins was
investigated. MDCK cells and GLB1-/- fibroblasts were transfected
with ss-ECFP-(-iss)-GLB1delEx15-His and ss-ECFP-(-iss)-GLB1-
19bpdupl-His vectors. In comparison with the wild type GLB1 pro-
tein, the mutant GLB1 proteins were inactive (Fig. 6). Moreover,
the intracellular localization of these mutant proteins was
observed by confocal microscopy after specific staining of the
lysosomes with LysoTracker. For this purpose, MDCK cells were
transfected with ss-ECFP-(-iss)-GLB1delEx15-His and ss-ECFP-
(-iss)-GLB1-19bpdupl-His vectors. As the wild type protein, a
fraction of the mutant proteins was also located in the lysosomes 
(Fig. 7A and B). Similar results were obtained after staining the
lysosomes with LAMP-1 antibody (data not shown).
To determine whether the mutant proteins are proteolytically
modified at the lysosomal level Western blot analyses with anti-
bodies against ECFP and His-tag were performed. It was observed
that the N-terminal processing of the mutant proteins and wild
type protein was identical. Thus, the mutant precursor proteins of
100,5 kD and 101,2 kD respectively were both processed to the 
90 kD and 44 kD fragments like the wild type precursor protein
(Fig. 8A; lines 1,2 and 3). In contrast, the C-terminal processing of
the mutant proteins differed from the wild type protein as
assessed by variations in the small polypeptide bands, 20 kD for
the wild type protein (Figure 8 B; line 1) compared to a 11 kD for
the GLB1delEx15 (Fig. 8B; line 2) and no polypeptide for the
GLB1-19bpdupl mutant  (Fig. 8B; line 3).
Fig. 4 Localization of wild-type canine GLB1 in MDCK cells transfected with ss-ECFP-(-iss)-GLB1-His construct; confocal microscopy analyses revealed
the lysosomal localization of wild-type GLB1; I, lysosomes stained with LysoTracker (red); II, wild-type canine GLB1 detected by ECFP fluorescence (green);
III, co-localization of LysoTracker and GLB1 (amber); magnification 630.
Fig. 5 Processing of wild-type ECFP fused GLB1 in MDCK cells; the
Western blot images shown the lysosomal maturation of wild-type
GLB1 as indicated by the presence of the 90 kD (A, line 1) and 
20 kD (B, line1) bands, in comparison with the ER resident GLB1
protein (A, B, lines 2) (A) 110 kD canine GLB1 precursor protein 
(84 kD precursor GLB1 + 26 kD ECFP), 90 kD processed fragment
(64 kD mature GLB1 + 26 kD ECFP) and 44 kD fragment (18 kD
GLB1 fragment + 26 kD ECFP) were detected using anti-ECFP anti-
body; (B) 110 kD canine GLB1 precursor protein (84 kD precursor
GLB1 + 26 kD ECFP) and 20 kD polypeptide was observed using anti-
His-antibody; an unspecific band of ~40 kD appeared in Figure 5B
line 1 and 2.
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Discussion
In the present study, the intracellular localization, processing, and
enzymatic activity of the wild type and two mutant GLB1 proteins
were investigated in a canine model of GM1-gangliosidosis with
the ultimate goal to elucidate the patho-mechanism of GM1-gan-
gliosidosis [4, 14].
Using clinical and biochemical data it was demonstrated that
GM1-gangliosidosis in dogs resembled its human counterpart to a
higher extent than GM1-gangliosidosis in genetically engineered
mice [12, 16, 35–37]. Unlike in humans, a regulatory mechanism
in the murine brain involving an active desialylating enzyme
reduces the GM1-ganglioside accumulation thus leading to high
levels of asialo-GM1 (GA1). In this model it is difficult to differenti-
ate the phenotypic effects of GM1 from those of GA1 accumulation.
Moreover, due to this molecular system, high levels of GM1, typi-
cal for types I and II GM1-gangliosidosis are attained in genetically
engineered mice only at an adult age [38–40].
For further therapeutic approaches, the similarities between
canine and human GLB1 were investigated at the molecular level.
Furthermore, the role of canine GLB1 mutants in onset of GM1-
gangliosidosis was also elucidated.
Firstly, structural features, lysosomal transport and maturation
of canine GLB1 were investigated and compared to human GLB1.
Both enzymes have an identical cleavage sequence for proteolytic
maturation in lysosomes (N542S↓SNYT LPAFYMGGNPF555) [22)
26]. This demonstrated that the canine GM1-gangliosidosis resem-
bled its human counterpart not only at the clinical, but also at the
molecular level.
To determine whether the lack of GLB1 activity observed in
affected dogs is the result of an abnormal transport through the
cell or is a consequence of abnormal proteolytic processing of the
C-terminus, the influence of two distinct genetic modifications in
the GLB1 mRNA on the intracellular trafficking of the correspon-
ding proteins was investigated. 
Both cell types analysed, MDCK cells and canine GLB1+/+
fibroblasts, revealed a similar high level of endogenous GLB1
activity, in comparison with canine GLB1-/- canine fibroblasts, that
had almost undetectable levels of GLB1 [14]. After transfection
with ss-ECFP-(-iss)-GLB1-His vector, the GLB1 activity in canine
GLB1-/- fibroblasts as well as in MDCK cells increased substantially.
In transfected canine GLB1-/- fibroblasts, the GLB1 activity
reached the level of non-transfected canine GLB1+/+ fibroblasts.
Interestingly, in the immortal MDCK cells transfected with the ss-
ECFP-(-iss)-GLB1-His construct, the GLB1 activity exceeded that
of non-transfected MDCK cells. In GLB1-/- fibroblasts transfected
with the same construct the GLB1 activity did not increase above
the GLB1 activity found in  primary non-transfected GLB1+/+
fibroblasts. The observed differences between the immortal cell
Fig. 6 Comparison between the enzymatic activities of wild-type and mutant GLB1 proteins in MDCK cells and GLB1-/- fibroblasts; the data shown that
GLB1 activity (mU/mg) increased after transfection with the wild type GLB1 containing vector, whereas in cells transfected with the constructs which
encodes for mutant GLB1 proteins the GLB1 activity decreased under the levels of non-transfected cells. ss-ECFP – GLB1 activity in cells transfected with
the ss-ECFP construct; ss-ECFP-(-iss)-GLB1-His - GLB1 activity in cells transfected with ss-ECFP-(-iss)-GLB1-His construct which encodes for the wild-
type GLB1; ss-ECFP-(-iss)-GLB1delEx15-His - GLB1 activity in cells transfected with ss-ECFP-(-iss)-GLB1delEx15-His construct which encodes the mutant
GLB1 without the sequence encoded by exon 15; ss-ECFP-(-iss)-GLB1-19bpdupl-His -  GLB1 activity in cells transfected with ss-ECFP-(-iss)-GLB1-19bpdu-
pl-His construct which encodes the mutant GLB1 harboring the 19 bp duplication inside the exon 15 sequence.
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line (MDCK) and the primary cells (GLB1+/+ fibroblasts) suggest-
ed the presence of an intracellular restrictive factor which protects
the primary cells from entering into premature cellular senescence
by limiting an increase in GLB1 activity over the level of primary
GLB1+/+ fibroblasts [41–43]. Differences between immortalized
and primary cells regarding senescence-associated GLB1 (wild
type GLB1) activities were already described [44]. The activity of
GLB1 depends largely on protective protein/cathepsin A (PPCA)
which forms oligomers with GLB1 in a strict regulated molecular
ratio of 8 to 4. These complexes are essential for the correct
folding and the transport of human GLB1 into the lysosomes,
hereby acting as a possible GLB1 activity restrictive factor
[45–47]. In view of the great similarity between the human and
canine GLB1 it is plausible to propose a similar complex formation
between GLB1 and PPCA with a comparable molecular ratio for
the canine lysosomal multienzymic complex [18, 35].
Interestingly, when MDCK cells were transfected with ss-ECFP-(-
iss)-GLB1delEx15 and ss-ECFP-(-iss)-GLB1-19bpdupl vectors the
GLB1 activity decreased. This could be due to dimer formation
between wild type and mutant protein forms. Alternatively, it is
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Fig. 7 Intracellular localization of the canine GLB1-delEx15 (A) and GLB1-19bpdupl (B) mutant proteins in MDCK cells; the confocal images show lysoso-
mal localization of the mutant GLB1 proteins. IA, IB, lysosomes stained with the LysoTracker (red); IIA, IIB, mutant GLB1 lacking the nucleotide sequence
encoded by exon 15 (GLB1-delEx15) and mutant GLB1 containing exon 15 with the 19 bp duplication (GLB1-19bpdupl), respectively (green); IIIA, IIIB, co-
localization of LysoTracker with GLB1-delEx15 or GLB1-19 bpdupl (amber); magnification 630.
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likely that the transport behavior of the wild-type endogenous
enzyme is substantially hampered due to the reduction in the num-
ber of PPCA molecules, since part of these associated also with
the mutant proteins. Subsequently, these abnormal complexes
may decrease the activity of the wild type protein [26, 27].
Moreover, canine GLB1 localization analyses showed that only a
fraction of the wild-type protein was found in lysosomes suggest-
ing an inefficient transport into the lysosomes, probably due to an
insufficient concentration of PPCA [46]. Similar results were
observed after Western blot analyses, where only a fraction of wild
type precursor protein was processed at the C-terminal end to a
mature form of the enzyme. The processing occurs in analogy to
the situation in humans [20, 26].
As expected, analyses of GLB1 levels in GLB1-/- fibroblasts trans-
fected with constructs encoding the mutant proteins revealed that
the abnormal precursor proteins did not result in detectable enzy-
matic activity. Similar to humans the amino acid sequence encoded
by exon 15 and 16 is essential for the activity of canine GLB1 [26].
In humans, modifications in the polypeptide region encoded by these
exons have shown to induce major conformational changes and
impair the maturation of the GLB1 [5, 20, 24, 26]. Based on the
obtained results using both abnormal canine GLB1 variants
(GLB1delEx15 and GLB1-19bpdupl) it was demonstrated that in
dogs, similar to humans, a correct amino acid sequence in the C-ter-
minal region is a prerequisite for correct processing and precursor
maturation. Surprisingly, the lack of these amino acid sequences is
not important for the further transport of both mutant proteins to the
lysosomes. These observations indicated that the mannose-6-phos-
phate signal for lysosomal trafficking of canine GLB1 is not located
on the asparagine residues 499, 546 and 556 within exon 15. The
significant modifications at the C-terminus resulted in a different pro-
cessing of the mutant proteins in the lysosomes as compared to the
wild-type species. Thus, deletion of exon 15 in the canine GLB1-
delEx15 mutant and the subsequent elimination of the canonic cleav-
age site do not block cleavage. In fact, cleavage takes place via an
alternative cleavage recognition sequence that is presumably located
on the sequence encoded by the exon 14. Moreover, due to the pres-
ence of a proteolytic fragment with an apparent molecular weight of
18 kD (as a 44 kD hybrid molecule with the 26 kDa ECFP protein) in
all GLB1 variants, it can be assumed that a recognition cleavage site
is located in the amino acid sequence encoded by exon 4. The pres-
ent results differ significantly from previous reports, showing diverse
proteolytic fragments of canine GLB1 of 32 kDa and 60 kDa. Our
results more closely resemble the proteolytic cleavage described for
the human GLB1 [20,  24, 35, 48]. Altogether, the results of 
the present study revealed that canine GM1-gangliosidosis is an
appropriate animal model for the human late infantile form. Both
mutant protein precursors are enzymatically inactive, but are trans-
ported to the lysosomes indicating that the amino acid sequences
encoded by exons 15 and 16 are necessary for correct folding and
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Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 8 Processing of wild-type canine GLB1 (lane 1) and mutant GLB1delEx15 (lane 2) and GLB1-19bpdupl (lane 3) proteins; the Western blot images
shown that all GLB1 proteins are similar processed at the N-terminal end (A), but differentially cleaved at the C-terminal end. A - 110 kD (84 kD GLB1 + 
26 kD ECFP), 100.5 kD (74.5 kD GLB1delEx15 + 26 kD ECFP) and 101.2 kD (75.2 kD GLB1-19bpdupl + 26 kD ECFP) precursor proteins; 90 kD processed
fragments (64 kD mature GLB1/ GLB1delEx15/ GLB1-19bpdupl + 26 kD ECFP) and 44 kD proteolytic fragments (18 kD GLB1/ GLB1delEx15/ GLB1-19bpdu-
pl + 26 kD ECFP) were observed with anti-ECFP antibody; (B) 110 kD (84 kD GLB1 + 26 kD ECFP), 100.5 kD (74.5 kD GLB1delEx15 + 26 kD ECFP) and
101.2 kD (75.2 kD GLB1-19bpdupl + 26 kD ECFP) precursor proteins were observed with His antibody; using the same antibody in lane 1 was observed a
20 kD cleavage product while in lane 2 a 11 kD cleavage product was detected.
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association with PPCA, whereas the routing to the lysosomes is not
influenced. In addition the present study showed that the investigat-
ed canine model represents a suitable platform for developing ther-
apeutic strategies in both human late infantile (type II) and canine
GM1-gangliosidosis.
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